During the forecast period, the Global Helicobacter Pylori Non-Invasive Testing Market Sales is expected to grow at a moderate 4.4% CAGR. The Helicobacter Pylori Non-Invasive Testing market is expected to be worth US$ 650.50 million in 2023. The market for Helicobacter Pylori Non-Invasive Testing is expected to be worth US$ 1000.57 millio by 2033.
Helicobacter Pylori Non-Invasive Testing is a crucial diagnostic approach used to detect the presence of H. pylori bacteria in the gastrointestinal tract without the need for invasive procedures. This bacterium is known to cause various gastrointestinal conditions, including gastritis, peptic ulcers, and even stomach cancer. Non-invasive tests are preferred as they are simpler, safer, and more comfortable for patients. The two most common non-invasive testing methods are the H. pylori stool antigen test and the H. pylori breath test. In the stool antigen test, a stool sample is collected and analyzed for the presence of H. pylori antigens, which are specific proteins produced by the bacteria. On the other hand, the breath test involves the patient ingesting a solution containing a stable isotope-labeled urea. If H. pylori is present, it produces an enzyme called urease, which breaks down the urea into carbon dioxide and ammonia. The detection of labeled carbon dioxide in the patient’s breath indicates the presence of the bacterium.
Accelerate Your Journey to Excellence with Unmatched Efficiency! Claim Your Sample Now :
https://www.futuremarketinsights.com/reports/sample/rep-gb-15823
Non-invasive testing for Helicobacter pylori has revolutionized the diagnosis and management of H. pylori-related diseases. These tests offer high sensitivity and specificity, making them reliable tools for early detection and accurate diagnosis. Additionally, non-invasive testing eliminates the risks associated with invasive procedures like endoscopy, making it a preferred option for many patients, especially those with no alarming symptoms. It also allows for easier monitoring of treatment success or recurrence after therapy. Non-invasive tests are particularly useful in children and elderly patients, who may have difficulty tolerating invasive procedures. As research and technology continue to advance, these non-invasive testing methods are expected to become even more efficient, cost-effective, and accessible, further improving the management of H. pylori infections and associated gastrointestinal conditions.
Key Takeaways:
- Demand for helicobacter pylori (H. pylori) non-invasive tests is anticipated to be driven by the rise in non-invasive testing for H. pylori diagnosis and the lack of endoscopic facilities.
- The non-invasive testing demand for helicobacter pylori (H. pylori) is expanding due to increasing government awareness of infection and the need for accurate diagnosis, rising demand for point-of-care testing equipment, and the widespread availability of diagnostics tests.
- The helicobacter pylori (H. pylori) non-invasive testing demand is anticipated to grow as a result of factors such as the increasing prevalence of H. pylori infection, the introduction of new products, and the approval of these products by the Food and Drug Administration.
- The global ageing population and the rising number of people with stomach ulcers are expected to fuel the growth of the Helicobacter Pylori Non-Invasive Testing market.
- The adoption of non-invasive testing for helicobacter pylori (H. pylori) is expected to grow during the projected period due to rising technical developments and an increase in innovations.
- The demand for non-invasive tests to identify helicobacter pylori (H. pylori) is projected to face challenges such as a low detection rate, the fact that H. pylori infection often has no symptoms, and strict regulatory regulations.
Unlock Exclusive Market Segments Insights: Buy Now:
https://www.futuremarketinsights.com/request-discount/rep-gb-15823
Segmentation Insights:
The clinic market is predicted to increase at a CAGR of more than 6% from 2023 to 2033, as more individuals choose clinics than hospitals due to reduced costs and higher quality of service. This is because people are more likely to seek assistance from clinics since they provide high-quality care and respond rapidly to patient demands, resulting in effective treatment at a cheap price. Clinics’ premium services as a result of effective illness management strategies are also predicted to drive market expansion.
POC testing accounted for more than 35% of the company due to its non-invasive nature and ability to provide quick results. This is due, in large part, to increased R&D spending and collaborative research activities among industry heavyweights, which stimulate innovation and new product development.
The non-invasive helicobacter pylori testing market may be divided into two main subsegments: invasive helicobacter pylori tests and non-invasive helicobacter pylori tests. Because rapid urease tests are both effective and affordable, this market subsegment is predicted to increase at a 6.5% CAGR between 2023 and 2032. Patients who do not respond well to antibiotics, have severe gastrointestinal symptoms, and require gastric endoscopy have a high demand for invasive diagnostic procedures.
Competitive Landscape:
Key Players
- DiaSorin S.p.A.
- Meridian Bioscience, Inc
- Exalenz Bioscience Ltd
- Alere
- Certest Biotec S.L.
- Sekisui Diagnostics
- CorisBioconcept SPRL
Insights Designed for You: Customize Your Exclusive Report Today :
https://www.futuremarketinsights.com/customization-available/rep-gb-15823
Key Segments in the Helicobacter Pylori Non-Invasive Testing Market
By Non-invasive Test Type:
- Serology Test
- Stool Antigen Test
- Urea Breath Test
By Test Type:
- Laboratory-based Tests
- Point-of-Care Tests
By End-user:
- Hospitals
- Diagnostic Labs
- Clinics
By Region:
- North America
- Latin America
- Asia Pacific
- MEA (Middle East and Africa)
- Europe
Recent Developments:
The FDA cleared Meridian Bioscience, Inc. to market its novel Curian and Curian HpSA assays in March of 2020. The new analyzer and initial assay are critical components of their plan to maintain market dominance in the testing of gastrointestinal diseases.
Thermo Fischer Scientific, a world-renowned provider of clinical research services to the biopharma and biotech industries, announced in December 2021 that it is expected to acquire PPD, Inc. for US$17.4 billion.
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, Stevie Award – recipient market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube
